Apnimed, Inc. — SEC Form D Filing

Apnimed, Inc. filed an SEC Form D on March 27, 2026, reporting $25.00M raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
March 27, 2026
Amount reported
$25.00M
Industry
Pharmaceuticals
Website
https://apnimed.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Many individuals suffer from obstructive sleep apnea (OSA) and are untreated or undertreated, leading to health complications due to lack of proper oxygenation and restorative sleep.

Solution

Apnimed develops novel oral therapies like AD109 that target the underlying issues of sleep-related breathing diseases to improve oxygenation and simplify treatment for patients.

Verdict

Investors said yes at this moment because they saw an opportunity in tackling a pervasive health issue with a novel oral therapy approach, not because the existing treatment landscape was clear or showed strong demand signals. They were implicitly betting on the possibility that a straightforward solution to obstructive sleep apnea would encourage patient compliance and market adoption. However, the limited upside stems from a crowded field of sleep disorder treatments that may dilute the potential market impact and the durability of the solution.

Source: SEC EDGAR Form D filing